Page 64 - Approval Program News Today

Alzheimer’s Disease is a progressive type of dementia with no cure. The FDA has approved 5 drugs for treating symptoms and one that may slow cognitive decline.

The growing prevalence of Alzheimer's disease is a frightening national emergency. The disease afflicts 6.2 million Americans, a number expected to more than double by 2060.

On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved Biogen, Inc.'s Aduhelm (aducanumab) to treat Alzheimer's disease through the FDA Accelerated Approval Program in a...

What you need to know about the fallout from the FDA decision to approve Biogen's Alzheimer's drug.

Share this article Share this article NEW ORLEANS, May 7, 2021 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Tricida, Inc. (NasdaqGS: TCDA).   On July 15, 2020, the Company disclosed that it received a notification from the U.S. Food and Drug Administration (FDA) regarding its ongoing review of the Companys New Drug Application (NDA) for its ...

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said Wednesday that the US Food and Drug Administration Oncologic Drugs Advisory Committee or ODAC voted 10 to 1 in favour of maintaining accelerated

28.04.2021 - Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favour of maintaining accelerated approval of Tecentriq (atezolizumab) ... Seite 1

F. Hoffmann-La Roche Ltd US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Co...

28.04.2021 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favor of maintaining accelerated approval of Tecentriq ... Seite 1

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq ® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express high levels of PD-L1 (PD-L1–stained tumor-...